Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs
| Autor: | Jing‑Jing Lin, Hong‑Feng Yan, Binbin Li, Yu‑Zhong Duan, Song Guo, Bei‑Ning Zhang, Zheng‑Yang Chen, Yan Cui, Jin‑Lian Zhou, Jun Wang, Ao Li, Ru‑Yi Yan, Xiao Yan Fu, He‑Ming Yang, Nan Jiang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Drug resistance Review Metastasis Targeted therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Immunology and Microbiology (miscellaneous) Trastuzumab Internal medicine medicine Abemaciclib business.industry Cancer General Medicine medicine.disease 030104 developmental biology chemistry 030220 oncology & carcinogenesis Neratinib business medicine.drug |
| Popis: | Human epidermal growth factor receptor-2 positive breast cancer (HER2+ BC) is characterized by a high rate of metastasis and drug resistance. The advent of targeted therapy drugs greatly improves the prognosis of HER2+ BC patients. However, drug resistance or severe side effects have limited the application of targeted therapy drugs. To achieve more effective treatment, considerable research has concentrated on strategies to overcome drug resistance. Abemaciclib (CDK4/6 inhibitor), a new antibody-drug conjugate (ADC), src homology 2 (SH2) containing tyrosine phosphatase-1 (SHP-1) and fatty acid synthase (FASN) have been demonstrated to improve drug resistance. In addition, using an effective vector to accurately deliver drugs to tumors has shown good application prospects. Many studies have also found that natural anti-cancer substances produced effective results during in vitro and in vivo anti-HER2+ BC research. This review aimed to summarize the current status of potential clinical drugs that may benefit HER2+ BC patients in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|